Shares of 10x Genomics (TXG) have gained 14.7% over the past four weeks to close the last trading session at $9.49, but there ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

TXG BLFS NAGE AZTA ADPT MLAB Company Name 10x Genomics, Inc. BioLife Solutions, Inc. Niagen Bioscience, Inc. Azenta, Inc. Adaptive Biotechnologies Corporation Mesa Laboratories, Inc. Sector Health ...

10x Genomics TXG shares soared 8.2% in the last trading session to close at $16.99. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

In trading on Thursday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 26.9, after changing hands as low as $20.13 per share. By comparison ...

Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...